Selective Removal of 7KC by a Novel Atherosclerosis Therapeutic Candidate Reverts Foam Cells to a Macrophage-like Phenotype.

The removal of the toxic oxidized cholesterol, 7-ketocholesterol (7KC), from cells through the administration of therapeutics has the potential to treat atherosclerosis and various other pathologies. While cholesterol is a necessary building block for homeostasis, oxidation of cholesterol can lead to the formation of toxic oxysterols involved in various pathologies, the most prominent of which is 7KC, which is formed through the non-enzymatic oxidation of cholesterol. Oxidized LDL (oxLDL) particles, highly implicated in heart disease, contain high levels of 7KC, and molecular 7KC is implicated in the pathogenesis of numerous diseases, including multiple sclerosis, hypercholesterolemia, sickle cell anemia, and multiple age related diseases. Of particular interest is the role of 7KC in the progression of atherosclerosis, with several studies associating elevated levels of 7KC with the etiology of the disease or in the transition of macrophages to foam cells. This research aims to elucidate the molecular mechanisms of UDP-003, a novel therapeutic, in mitigating the harmful effects of 7KC in mouse and human monocyte and macrophage cell lines. Experimental evidence demonstrates that administration of UDP-003 can reverse the foam cell phenotype, rejuvenating these cells by returning phagocytic function and decreasing both reactive oxygen species (ROS) and intracellular lipid droplet accumulation. Furthermore, our data suggests that the targeted removal of 7KC from foam cells with UDP-003 can potentially prevent and reverse atherosclerotic plaque formation. UDP-003 has the potential to be the first disease-modifying therapeutic approach to treating atherosclerotic disease.

Cyclodextrin dimers: A versatile approach to optimizing encapsulation and their application to therapeutic extraction of toxic oxysterols.

We have developed a novel class of specifically engineered, dimerized cyclodextrin (CD) nanostructures for the encapsulation of toxic biomolecules such as 7-ketocholesterol (7KC). 7KC accumulates over time and causes dysfunction in many cell types, linking it to several age-related diseases including atherosclerosis and age-related macular degeneration (AMD). Presently, treatments for these diseases are invasive, expensive, and show limited benefits. CDs are cyclic glucose oligomers utilized to capture small, hydrophobic molecules. Here, a combination of in silico, in vitro, and ex vivo methods is used to implement a synergistic rational drug design strategy for developing CDs to remove atherogenic 7KC from cells and tissues. Mechanisms by which CDs encapsulate sterols are discussed, and we conclude that covalently linked head-to-head dimers of ßCDs have substantially improved affinity for 7KC compared to monomers. We find that inclusion complexes can be stabilized or destabilized in ways that allow the design of CD dimers with increased 7KC selectivity while maintaining an excellent safety profile. These CD dimers are being developed as therapeutics to treat atherosclerosis and other debilitating diseases of aging.

Adsorption and desorption of cationic malachite green dye on cellulose nanofibril aerogels.

Ultra-light aerogels have been assembled from cellulose nanofibrils into hierarchically macroporous (several hundred µm) honeycomb cellular structure surrounded with mesoporous (8-60nm) thin walls. The high specific surface (193m2/g) and surface carboxyl content (1.29mmol/g) of these aerogels were demonstrated to be highly capable of removing cationic malachite green (MG) dye from aqueous media. The rapid MG adsorption was driven by electrostatic interactions and followed a pseudo-second-order adsorption kinetic and monolayer Langmuir adsorption isotherm. At a low 1:5mg/mL aerogel/MG ratio, both initial MG adsorption rate (2.3-59.8mgg-1min-1) and equilibrium adsorption capacity (53.0-203.7mgg-1) increased with increasing initial MG concentrations from 10 to 200mg/L, reaching a maximum adsorption of 212.7mgg-1. The excellent dye removal efficiency was demonstrated by complete MG removal through four repetitive adsorptions at a low 1:5mg/mL aerogel/MG ratio and 10mg/L dye concentration as well as 92% MG adsorption in a single batch at one order of magnitude higher10:5mg/mL aerogel/MG ratio and 100mg/L dye concentration. The adsorbed MG in aerogels could be desorbed in aqueous media by increasing ionic strength, demonstrating facile recovery of both dye and aerogel as well as the robust capability of this aerogel for repetitive applications.